ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ...
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events | International Journal of Gynecologic Cancer
The kinase polypharmacology landscape of clinical PARP inhibitors | Scientific Reports
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) | BMC Cancer | Full Text
ASCO GU 2020: Rucaparib for Recurrent, Locally Advanced, or Metastatic Urothelial Carcinoma (mUC): Results from ATLAS, A Phase II Open-Label Trial
Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
![PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52c115c5bf799368014e6b136b39cae306751b37/3-Figure1-1.png "PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar")
PDF] Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer | Semantic Scholar
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Blockbuster status competition intensifying for PARP inhibitors - Pharmaceutical Technology
Pharmacological profile of olaparib, veliparib and rucaparib across 29... | Download Scientific Diagram
Clovis Oncology Announces Availability of Rubraca®▽ (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Germany | Business Wire
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial - ScienceDirect
Rucaparib – second PARP inhibitor hits the market for ovarian cancer | MDedge Hematology and Oncology
ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-deficient mCRPC: Updated Analyses
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic Cancer - Penn Medicine
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology
The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial
ASCO GU 2022: A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) | Nature Communications
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial - The Lancet Oncology
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo- controlled, phase 3 trial - The Lancet
Rucaparib: the past, present, and future of a newly approved PARP inhi | OTT
